Skip to main content
    P

    ProQR Therapeutics BV (PRQR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.18
    -0.23 (-16.31%)

    Market Cap: $199.28M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    ProQR Therapeutics BV (PRQR) Financials: Revenue, Profit and Cash Flow

    Updated Aug 13, 2026. Financial statements from company filings, amounts in EUR.

    ProQR Therapeutics BV reported revenue of EUR 15.28M for the fiscal year ended Dec 31, 2025, down 19.2% from the year before. That year, net income was EUR -40.52M with a net margin of -265.2%, operating cash flow was EUR -52.79M and free cash flow was EUR -53.81M. The quarter ended Jun 30, 2026 had revenue of EUR 8.90M and net income of EUR -8.87M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from EUR 2.28M, a compound annual rate of 23.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 202515.28M-19.2%83.0%-275.9%-265.2%
    Dec 202418.91M+190.2%100.0%-161.2%-146.9%
    Dec 20236.51M+81.2%100.0%-489.1%-431.7%
    Dec 20223.59M+169.2%100.0%-1813.0%-1792.5%
    Dec 20211.33M+29.7%100.0%-4285.4%-4549.8%
    Dec 20201.03M-46.8%100.0%-4117.4%-4525.3%
    Dec 20191.93M-60.9%-5943.6%-2971.8%-2935.6%
    Dec 20184.94MN/A80.1%-734.5%-746.7%
    Dec 2017-1.53M-167.0%N/AN/AN/A
    Dec 20162.28MN/A43.8%-1734.1%-1713.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue15.28M18.91M6.51M3.59M1.33M1.03M1.93M4.94M-1.53M2.28M
    Cost of revenue2.60MN/A133.52K2.48MN/A2.19M116.82M983.51K1.00M1.28M
    Gross profit12.68M18.91M6.51M3.59M1.33M1.03M-114.89M3.96M-2.53M1.00M
    Research and development40.72M36.36M25.15M50.87M42.22M38.13M46.49M29.51M31.15M31.92M
    Operating income-42.15M-30.47M-31.86M-65.16M-57.21M-42.37M-57.45M-36.29M-40.50M-39.57M
    Net income-40.52M-27.76M-28.12M-64.42M-60.74M-46.56M-56.75M-36.89M-43.64M-39.10M
    EBITDA-36.93M-24.12M-24.10M-56.46M-54.95MN/AN/A-35.28M1.06M-35.96M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue8.90M2.07M4.64M2.92M3.82M4.52M4.31M3.84M6.30M4.45M3.28M1.37M
    Gross profit8.19M1.36M3.97M2.92M3.82M4.52M4.31M3.84M6.30M4.45M3.28M1.37M
    Operating incomeN/A-13.87M-9.04M-11.28M-12.25M-10.82M-10.08M-8.72M-3.60M-8.07M-6.27M-7.39M
    Net income-8.87M-13.60MN/A-11.01M-12.18M-10.08M-9.30M-8.11M-2.69M-7.66M-5.48M-5.71M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of EUR 5.22M by 103.32M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets132.43M173.92M152.31M182.84M238.33M120.80M131.93M110.23M63.77M69.13M
    Current assets117.59M159.31M133.65M164.85M217.75M97.91M128.71M108.37M60.71M65.41M
    Cash and equivalents108.53M154.71M131.37M101.15M213.25M92.79M125.66M105.58M57.76M62.44M
    Total liabilities74.44M82.22M106.59M111.68M109.57M51.61M26.61M17.55M16.54M13.09M
    Short-term debt5.22M4.62M1.78M4.15M7.17M2.93M955.25K7.00K2.35M0
    Long-term debtN/AN/A4.29M4.27M39.32M16.19M12.71M9.39M5.28M5.70M
    Shareholder equity57.99M91.70M45.72M71.58M129.45M69.85M105.88M92.69M47.27M56.05M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets133.50M114.11M112.71M146.11M161.45M163.85M173.92M119.25M126.52M133.79M152.31M150.38M
    Total liabilities54.05M70.79M63.36M79.05M82.82M78.59M82.22M91.37M91.31M96.18M106.59M101.32M
    Cash and equivalents117.08M93.43M92.37M125.59M140.59M143.03M154.71M99.78M84.64M92.57M131.37M127.63M
    Shareholder equity79.44M43.32M49.35M67.06M78.63M85.27M91.70M27.88M35.21M37.61M45.72M49.06M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-52.79M-36.39M21.55M-68.51M-26.01M-47.06M-43.97M-30.68M-34.95M-34.22M
    Capital expenditures1.02M1.42M1.37M708.00K484.00K924.00K580.00K312.00K121.00K2.54M
    Free cash flow-53.81M-37.81M20.18M-69.22M-26.50M-47.98M-44.55M-30.99M-35.07M-36.76M
    Investing cash flow-1.02M-4.07M4.28M-702.00K-425.00K-924.00K-580.00K-312.00K-121.00K-2.54M
    Financing cash flow-1.84M70.28M-2.27M-30.89M136.83M14.50M50.20M88.65M26.64M357.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-12.40M-11.14M-13.07M-12.23M-11.40M-15.80M-9.35M-5.66M-6.26M-15.13M-5.32M-7.51M
    Capital expenditures294.78K164.00KN/A169.00K101.00K224.00K133.00K286.00K267.00K732.00K602.00K339.00K
    Free cash flow-12.70M-11.31MN/A-12.40M-11.50M-16.02M-9.48M-5.94M-6.52M-15.86M-5.92M-7.85M
    Last 12 quarters

    Frequently Asked Questions About PRQR

    What is ProQR Therapeutics BV's annual revenue?

    ProQR Therapeutics BV reported revenue of EUR 15.28M for the fiscal year ended Dec 31, 2025.

    How fast is ProQR Therapeutics BV's revenue growing?

    Revenue was down 19.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 62.0%.

    Is ProQR Therapeutics BV profitable?

    No. ProQR Therapeutics BV reported net income of EUR -40.52M for the fiscal year ended Dec 31, 2025, with a net margin of -265.2%.

    How much free cash flow does PRQR generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of EUR -52.79M minus capital expenditures of EUR 1.02M produced free cash flow of EUR -53.81M.

    How much debt does ProQR Therapeutics BV have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of EUR 5.22M and cash and equivalents of EUR 108.53M.